TransMedics Valuation Multiples

TransMedics Overview

About TransMedics

TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System (OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization, and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.

Founded

2018

HQ

Employees

898

Website

transmedics.com

Sectors

Medical DevicesDeepTechHealthTech

Financials (LTM)

Revenue: $646M

EBITDA: $160M

EV

$4B

Valuation Multiples

Multiples.vc

Start free trial

TransMedics Financials

TransMedics reported last 12-month revenue of $646M and EBITDA of $160M.

In the same LTM period, TransMedics generated $387M in gross profit, $160M in EBITDA, and $164M in net income.

TransMedics P&L

In the most recent fiscal year, TransMedics reported revenue of $605M and EBITDA of $161M.

TransMedics expects next 12-month revenue of XXX and NTM EBITDA of XXX

TransMedics Stock Performance

TransMedics has current market cap of $4B, and enterprise value of $4B.

TransMedics' stock price is $115.87.

TransMedics Valuation Multiples

TransMedics trades at 6.2x EV/Revenue multiple, and 25.2x EV/EBITDA.

TransMedics Financial Valuation Multiples

As of April 20, 2026, TransMedics has market cap of $4B and EV of $4B.

Equity research analysts estimate TransMedics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

TransMedics has a P/E ratio of 24.4x.

TransMedics Margins & Growth Rates

TransMedics' revenue in the last 12 month grew by 21%.

TransMedics' revenue per employee in the last FY averaged $0.7M, while opex per employee averaged $0.3M for the same period.

TransMedics' rule of 40 is 43% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

TransMedics' rule of X is 77% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

TransMedics Public Comps

See public comps and valuation multiples for other Medical Devices comps.

TransMedics M&A Activity

TransMedics acquired XXX companies to date.

Last acquisition by TransMedics was on XXXXXXXX, XXXXX. TransMedics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

TransMedics Investment Activity

TransMedics invested in XXX companies to date.

TransMedics made its latest investment on XXXXXXXX, XXXXX. TransMedics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).